News Digest / Ticker: MLYS

Ticker: MLYS

06:06pm, Tuesday, Aug 12, 2025

Mineralys posts pivotal wins, readies pre‑NDA with $325M but faces high cash burn, safety risks

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) - quick read Snapshot - what's happening inside * Company is a clinical‑stage biotech focused on lorundrostat (aldosterone synthase inhibitor) across uncontrolled/resistant hypertension, CKD and obstructive sleep apnea. * Pivotal trials Launch‑HTN and ...

06:00pm, Monday, May 12, 2025

Mineralys Therapeutics Faces Challenges with Increased Losses Amid Promising Drug Development Progress

Company OverviewMineralys Therapeutics, Inc. (NASDAQ: MLYS) is a clinical-stage biopharmaceutical company focused on developing treatments for diseases driven by dysregulated aldosterone. The company is advancing its lead product candidate, lorundrostat, for hypertension and related conditions. A...